Synthetic Universal Flu Vaccine

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43IP001108-01A1
Agency Tracking Number: R43IP001108
Amount: $224,966.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCIRD
Solicitation Number: PA17-302
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-30
Award End Date (Contract End Date): 2020-03-29
Small Business Information
1616 EASTLAKE AVE E STE 260, Seattle, WA, 98102-3739
DUNS: 831016907
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 CHRISTOPHER CLEGG
 (206) 826-7900
 chris.clegg@immunedesign.com
Business Contact
 CHRISTOPHER CLEGG
Phone: (206) 819-9413
Email: cclegg@triabio.com
Research Institution
N/A
Abstract
Abstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is the risk of choosing the wrong vaccine strainwhich leads to sharp drops in efficacy and increased infection ratesNew transformational technologies are needed to combat InfluenzaThe best solution is a universal vaccine that will establish longterm immunity against all genetic strainsThis can only be accomplished by constructing vaccines around highly conserved protein sequences common to all virusesImportantlythese antigens are known and numerous studies indicate that vaccines targeting linear epitopes withinviral proteins can be used to induce protective antibodies against both Type A and Type B virusesTRIA Bioscience is developing a self assembling peptide nanoparticle vaccine platform that incorporates these and similar linear B cell epitopes directly into synthetic peptides capable of stimulating significant functional antibody responsesThe ease of production and formulation of such peptides makes this an ideal technology for mass productionWe propose to build a multivalent universal Influenza vaccine that targets these highly conserved epitopes and confers long lived immunity against multiple Influenza classes and strainsMice will be immunized with individual peptides to confirm that each epitope induces an antiviral antibody responseThe relative potency of each vaccine will be evaluated in mouse challenge studies and multivalent formulations will tested for improved protection against Influenza A and B viruses Narrative Influenza infection is an acute global health issue and new technologies are needed that can maximize vaccine immunogenicity and ease manufacturing constraintsTRIA Biosciences is developing a multivalent universal Flu vaccine using synthetic peptides

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government